PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 9288221-1 1997 Neuropeptide Y (NPY) is co-localized with noradrenaline (NA) in perivascular sympathetic nerve and is a vasoconstrictor. Norepinephrine 42-55 neuropeptide Y Homo sapiens 0-14 9458879-1 1998 Neuropeptide Y (NPY) is a vasoconstrictor peptide and a cotransmitter with norepinephrine (NE) in sympathetic nerve terminals and is thought to be involved in sympathetic nerve stimulation (SNS)-induced vasoconstriction. Norepinephrine 75-89 neuropeptide Y Homo sapiens 0-14 9458879-1 1998 Neuropeptide Y (NPY) is a vasoconstrictor peptide and a cotransmitter with norepinephrine (NE) in sympathetic nerve terminals and is thought to be involved in sympathetic nerve stimulation (SNS)-induced vasoconstriction. Norepinephrine 75-89 neuropeptide Y Homo sapiens 16-19 9214397-1 1997 Neuropeptide Y (NPY) is a peptide hormone that is expressed, stored, and released in sympathetic neurones together with noradrenaline. Norepinephrine 120-133 neuropeptide Y Homo sapiens 0-14 9214397-1 1997 Neuropeptide Y (NPY) is a peptide hormone that is expressed, stored, and released in sympathetic neurones together with noradrenaline. Norepinephrine 120-133 neuropeptide Y Homo sapiens 16-19 9786171-8 1998 Blockade experiments showed that the vasomotor responses to norepinephrine were blocked by prazosin, to NPY by BIBP 3226, acetylcholine by atropin, substance P by RP 67580, and the human alpha-CGRP response by human alpha-CGRP(8-37). Norepinephrine 60-74 neuropeptide Y Homo sapiens 104-107 9288221-1 1997 Neuropeptide Y (NPY) is co-localized with noradrenaline (NA) in perivascular sympathetic nerve and is a vasoconstrictor. Norepinephrine 42-55 neuropeptide Y Homo sapiens 16-19 9213209-5 1997 NPY, its endogenous analog, peptide YY, and its C-terminal fragment, NPY13-36, but not its analog, [Leu31,Pro34]NPY, concentration dependently (1-100 nM) inhibited [3H]noradrenaline release in all tissues studied. Norepinephrine 168-181 neuropeptide Y Homo sapiens 0-3 9213209-5 1997 NPY, its endogenous analog, peptide YY, and its C-terminal fragment, NPY13-36, but not its analog, [Leu31,Pro34]NPY, concentration dependently (1-100 nM) inhibited [3H]noradrenaline release in all tissues studied. Norepinephrine 168-181 neuropeptide Y Homo sapiens 69-72 9213209-4 1997 The effects of subtype-selective NPY analogs on the stimulation-induced noradrenaline release were studied. Norepinephrine 72-85 neuropeptide Y Homo sapiens 33-36 8911654-7 1996 For example, plasma NPY, a peptide co-localized with norepinephrine in the sympathetic nervous system, is low in patients with FM. Norepinephrine 53-67 neuropeptide Y Homo sapiens 20-23 8828539-2 1996 Neuropeptide Y (NPY) is co-localized with norepinephrine in sympathetic perivascular nerves. Norepinephrine 42-56 neuropeptide Y Homo sapiens 0-14 8828539-2 1996 Neuropeptide Y (NPY) is co-localized with norepinephrine in sympathetic perivascular nerves. Norepinephrine 42-56 neuropeptide Y Homo sapiens 16-19 8828539-3 1996 NPY is released with norepinephrine on sympathetic nerve stimulation and produces long-lasting vasoconstriction of the nasal vascular bed. Norepinephrine 21-35 neuropeptide Y Homo sapiens 0-3 8898322-4 1996 Decreased availability of estrogen may also increase the levels of neuropeptide Y, leading to decreased release of noradrenaline from the ventromedial hypothalamus. Norepinephrine 115-128 neuropeptide Y Homo sapiens 67-81 8898322-5 1996 The increased noradrenaline content may increase the concentration of galanin, which will decrease the circulating levels of insulin and increase the pace of transcription of the neuropeptide Y gene. Norepinephrine 14-27 neuropeptide Y Homo sapiens 179-193 9039093-1 1997 Neuropeptide Y coexists with norepinephrine in sympathetic nerves and is coreleased into the circulation on sympathetic activation. Norepinephrine 29-43 neuropeptide Y Homo sapiens 0-14 8982651-0 1996 Neuropeptide Y potentiates noradrenaline-induced contraction through the neuropeptide Y Y1 receptor. Norepinephrine 27-40 neuropeptide Y Homo sapiens 0-14 8982651-0 1996 Neuropeptide Y potentiates noradrenaline-induced contraction through the neuropeptide Y Y1 receptor. Norepinephrine 27-40 neuropeptide Y Homo sapiens 73-87 8982651-2 1996 Neuropeptide Y significantly potentiated the noradrenaline-induced contraction in non-incubated vessels (pEC50 6.4 +/- 0.2 vs. 5.9 +/- 0.2) and in vessels incubated with 1 microM Sense oligodeoxynucleotide (Sense) (pEC50 6.0 +/- 0.1 vs. 5.6 +/- 0.2). Norepinephrine 45-58 neuropeptide Y Homo sapiens 0-14 8982651-6 1996 On the basis of our results we conclude that the neuropeptide Y-induced potentiation of the noradrenaline-induced contraction is mediated by the neuropeptide Y Y1 receptor. Norepinephrine 92-105 neuropeptide Y Homo sapiens 49-63 8982651-6 1996 On the basis of our results we conclude that the neuropeptide Y-induced potentiation of the noradrenaline-induced contraction is mediated by the neuropeptide Y Y1 receptor. Norepinephrine 92-105 neuropeptide Y Homo sapiens 145-159 9116208-0 1996 Neuropeptide Y elevates intracellular Ca2+ and evokes noradrenaline release in SH-SY5Y cells. Norepinephrine 54-67 neuropeptide Y Homo sapiens 0-14 8370239-1 1993 Neuropeptide Y (NPY) is a peptide released together with noradrenaline (NA) from sympathetic nerve endings. Norepinephrine 57-70 neuropeptide Y Homo sapiens 0-14 8722501-1 1996 Neuropeptide Y is a sympathetic co-neurotransmitter released with noradrenaline upon sympathetic nerve stimulation. Norepinephrine 66-79 neuropeptide Y Homo sapiens 0-14 8529333-2 1995 Human neuropeptide Y is an endogenous vasoconstrictor peptide that is costored with norepinephrine in sympathetic nerve endings and coreleased with the catecholamine under various physiologic and pathologic conditions. Norepinephrine 84-98 neuropeptide Y Homo sapiens 6-20 8848409-1 1996 Neuropeptide Y (NPY) has been recently characterized as a circulating vasoconstrictor peptide which is co-stored with noradrenaline in sympathetic neurons. Norepinephrine 118-131 neuropeptide Y Homo sapiens 0-20 8746761-2 1996 Sympathetic nerve fibres, with their origin in the superior cervical ganglia, contain neuropeptide Y colocalized with norepinephrine. Norepinephrine 118-132 neuropeptide Y Homo sapiens 86-100 8748207-5 1995 Neuropeptide Y potentiated the mitogenic effect of noradrenaline, and together with adenosine 5"-triphosphate, the sympathetic cotransmitters reached a mitogenic effect of approximately 20% of fetal calf serum. Norepinephrine 51-64 neuropeptide Y Homo sapiens 0-14 7990977-2 1994 Local infusions of NPY had no measurable effect on venous tone, but coinfusion of a constant high dose of NPY (242 pmol/min) with noradrenaline caused a 2.9-fold increase in the mean ED50 for noradrenaline. Norepinephrine 130-143 neuropeptide Y Homo sapiens 106-109 7990977-2 1994 Local infusions of NPY had no measurable effect on venous tone, but coinfusion of a constant high dose of NPY (242 pmol/min) with noradrenaline caused a 2.9-fold increase in the mean ED50 for noradrenaline. Norepinephrine 192-205 neuropeptide Y Homo sapiens 106-109 7990977-5 1994 Although functional interactions between NPY or VIP and noradrenaline could be demonstrated, the dosages of the peptides required were high. Norepinephrine 56-69 neuropeptide Y Homo sapiens 41-44 7994163-1 1994 The aim of this experiment was to measure the concentration of neuropeptide Y (NPY), a vasoactive transmitter which co-exists with noradrenaline in sympathetic nerve terminals, in venous blood taken from the painful and contralateral limbs of 16 patients with features of reflex sympathetic dystrophy (RSD) or causalgia. Norepinephrine 131-144 neuropeptide Y Homo sapiens 63-77 7994163-1 1994 The aim of this experiment was to measure the concentration of neuropeptide Y (NPY), a vasoactive transmitter which co-exists with noradrenaline in sympathetic nerve terminals, in venous blood taken from the painful and contralateral limbs of 16 patients with features of reflex sympathetic dystrophy (RSD) or causalgia. Norepinephrine 131-144 neuropeptide Y Homo sapiens 79-82 8064781-1 1994 Neuropeptide Y (NPY) has been recently characterised as a circulating vasoconstrictor peptide which is co-stored with noradrenaline (NA) in sympathetic neurons. Norepinephrine 118-131 neuropeptide Y Homo sapiens 0-20 8016410-0 1994 Neuropeptide Y stimulates proliferation of human vascular smooth muscle cells: cooperation with noradrenaline and ATP. Norepinephrine 96-109 neuropeptide Y Homo sapiens 0-14 8205750-10 1994 Arterial insulin as well as Adr and noradrenaline increased with the combined NPY-and Adr infusion as with Adr alone. Norepinephrine 36-49 neuropeptide Y Homo sapiens 78-81 8132438-1 1994 Neuropeptide Y (NPY) is widely distributed throughout sympathetic nerve endings where it is co-stored and co-secreted with noradrenaline. Norepinephrine 123-136 neuropeptide Y Homo sapiens 0-14 8132438-1 1994 Neuropeptide Y (NPY) is widely distributed throughout sympathetic nerve endings where it is co-stored and co-secreted with noradrenaline. Norepinephrine 123-136 neuropeptide Y Homo sapiens 16-19 8370239-1 1993 Neuropeptide Y (NPY) is a peptide released together with noradrenaline (NA) from sympathetic nerve endings. Norepinephrine 57-70 neuropeptide Y Homo sapiens 16-19 8102190-2 1993 Neuropeptide Y (NPY), consisting of 36 amino acids, has been reported to coexist usually with noradrenaline in peripheral sympathetic neurons. Norepinephrine 94-107 neuropeptide Y Homo sapiens 0-14 7687716-1 1993 Neuropeptide Y (NPY), a potent vasoconstrictor agent reported to be released, in addition to norepinephrine (NE), by sympathetic nerve endings during stress, may contribute to the pressor response to various stimuli. Norepinephrine 93-107 neuropeptide Y Homo sapiens 0-14 7687716-1 1993 Neuropeptide Y (NPY), a potent vasoconstrictor agent reported to be released, in addition to norepinephrine (NE), by sympathetic nerve endings during stress, may contribute to the pressor response to various stimuli. Norepinephrine 93-107 neuropeptide Y Homo sapiens 16-19 8224732-4 1993 In the periphery, NPY coexists with noradrenaline (NA) in perivascular sympathetic fibers. Norepinephrine 36-49 neuropeptide Y Homo sapiens 18-21 8102190-2 1993 Neuropeptide Y (NPY), consisting of 36 amino acids, has been reported to coexist usually with noradrenaline in peripheral sympathetic neurons. Norepinephrine 94-107 neuropeptide Y Homo sapiens 16-19 8102190-7 1993 Present study revealed that NPY might be a possible neuromodulator in lower urinary tract, cooperating with noradrenaline. Norepinephrine 108-121 neuropeptide Y Homo sapiens 28-31 1582134-8 1992 Plasma noradrenaline fell by 20% (P less than 0.02) and arterial glucose by 3% (P less than 0.005) during the NPY infusion. Norepinephrine 7-20 neuropeptide Y Homo sapiens 110-113 7922157-2 1993 Neuropeptide Y is co-released with noradrenaline by perivascular nerve endings. Norepinephrine 35-48 neuropeptide Y Homo sapiens 0-14 1475406-3 1992 Neuropeptide Y (NPY) induces direct vasoconstriction and potentiates the action of noradrenaline. Norepinephrine 83-96 neuropeptide Y Homo sapiens 0-14 1475406-3 1992 Neuropeptide Y (NPY) induces direct vasoconstriction and potentiates the action of noradrenaline. Norepinephrine 83-96 neuropeptide Y Homo sapiens 16-19 1475406-5 1992 In order to determine if NPY could be involved in the enhanced vascular sensitivity to noradrenaline associated with adrenocortical hyperactivity, we measured plasma NPY in patients with Cushing"s syndrome (n = 26) and primary hyperaldosteronism (n = 15) and compared it with that of hypertensive patients with pheochromocytomas (n = 13) or essential hypertension (n = 51) and with normotensive controls (n = 47). Norepinephrine 87-100 neuropeptide Y Homo sapiens 25-28 1374311-4 1992 Since there was a direct correlation between plasma NPY before exercise and the increment (delta 80%) in noradrenaline during exercise (r = 0.54; P less than 0.01), it is suggested that plasma NPY determined in the basal situation may be a useful marker of sympathetic nerve failure in diabetic patients. Norepinephrine 105-118 neuropeptide Y Homo sapiens 52-55 1374311-4 1992 Since there was a direct correlation between plasma NPY before exercise and the increment (delta 80%) in noradrenaline during exercise (r = 0.54; P less than 0.01), it is suggested that plasma NPY determined in the basal situation may be a useful marker of sympathetic nerve failure in diabetic patients. Norepinephrine 105-118 neuropeptide Y Homo sapiens 193-196 8432288-3 1993 In both normal and heart failure patients, NPY-Li-decreased (296 +/- 73 to 233 +/- 63 pg.ml-1 and 652 +/- 36 to 516 +/- 25 pg.ml-1 (P < 0.01) respectively) in response to standing, whereas catecholamines increased in both groups (norepinephrine 203 +/- 73 to 507 +/- 165 pg.ml-1 and 493 +/- 197 to 813 +/- 336 pg.ml-1 (P < 0.001) respectively and epinephrine 23 +/- 12 to 38 +/- 12 pg.ml-1 and 46 +/- 19 to 62 +/- 28 pg.ml-1 (P < 0.001) respectively). Norepinephrine 233-247 neuropeptide Y Homo sapiens 43-46 1381830-8 1992 In the temporal artery, NPY did not induce contraction but potentiated the vasoconstrictor response to noradrenaline. Norepinephrine 103-116 neuropeptide Y Homo sapiens 24-27 1380602-1 1992 Animal experimental evidence suggests that neuropeptide Y (NPY) is coreleased with norepinephrine (NE) from sympathetic nerve endings and is involved in nonadrenergic neurogenic vascular control of skeletal muscle. Norepinephrine 83-97 neuropeptide Y Homo sapiens 43-57 1380602-1 1992 Animal experimental evidence suggests that neuropeptide Y (NPY) is coreleased with norepinephrine (NE) from sympathetic nerve endings and is involved in nonadrenergic neurogenic vascular control of skeletal muscle. Norepinephrine 83-97 neuropeptide Y Homo sapiens 59-62 1582134-10 1992 The results also suggest that elevated plasma NPY-levels may be associated with changes in the turnover of noradrenaline and glucose. Norepinephrine 107-120 neuropeptide Y Homo sapiens 46-49 1493849-7 1992 The data also suggested the existence of a slower elimination phase, with a half life of 13 h. The venous plasma concentration of noradrenaline (NA) increased 3-fold within 15 min after the yohimbine injection while plasma adrenaline (A) and neuropeptide Y-like immunoreactivity (NPY-LI) remained unchanged. Norepinephrine 130-143 neuropeptide Y Homo sapiens 280-283 1320891-1 1992 Neuropeptide Y, one of the most abundant polypeptides within the nervous system, is co-stored with catecholamines, especially norepinephrine (NE), thus suggesting its possible involvement in pathologies characterized by a noradrenergic impairment. Norepinephrine 126-140 neuropeptide Y Homo sapiens 0-14 1670626-3 1991 Neuropeptide Y (NPY), a 36-amino acid neuropeptide that is colocalized and released with norepinephrine from sympathetic nerves, has already been implicated in inflammatory reactions via modulation of histamine release from mast cells. Norepinephrine 89-103 neuropeptide Y Homo sapiens 0-14 1826401-6 1991 In contrast, vasoactive intestinal peptide has convincingly been demonstrated to stimulate thyroid hormone secretion, and neuropeptide Y to potentiate the inhibitory action of noradrenaline on TSH-induced thyroid hormone secretion. Norepinephrine 176-189 neuropeptide Y Homo sapiens 122-136 15815433-1 1992 Neuropeptide Y (NPY) a potent vasoconstrictor peptide, is co-stored with the classic neurotransmitter noradrenaline (NA) in certain peripheral sympathetic neurons and has been suggested to be a co-transmitter in vascular control. Norepinephrine 102-115 neuropeptide Y Homo sapiens 0-14 15815433-1 1992 Neuropeptide Y (NPY) a potent vasoconstrictor peptide, is co-stored with the classic neurotransmitter noradrenaline (NA) in certain peripheral sympathetic neurons and has been suggested to be a co-transmitter in vascular control. Norepinephrine 102-115 neuropeptide Y Homo sapiens 16-19 2035576-6 1991 Neuropeptide Y (10(-7) mol/L) often, but not always, enhanced the contraction induced by noradrenaline (10(-6) mol/L). Norepinephrine 89-102 neuropeptide Y Homo sapiens 0-14 1999028-2 1991 NPY coexists with noradrenaline in perivascular nerve terminals, may be released during sympathetic stimulation, and is a potent constrictor of the human coronary circulation and other vascular beds. Norepinephrine 18-31 neuropeptide Y Homo sapiens 0-3 1999028-3 1991 In vitro studies show that NPY can act either directly on vascular smooth muscle or indirectly by modulation of the presynaptic release or the postsynaptic actions of noradrenaline. Norepinephrine 167-180 neuropeptide Y Homo sapiens 27-30 1999028-5 1991 METHODS AND RESULTS: The effect on forearm blood flow of intra-arterial NPY was studied in six volunteers during coinfusion of noradrenaline and during reflex sympathetic stimulation induced by lower-body negative pressure. Norepinephrine 127-140 neuropeptide Y Homo sapiens 72-75 1670626-3 1991 Neuropeptide Y (NPY), a 36-amino acid neuropeptide that is colocalized and released with norepinephrine from sympathetic nerves, has already been implicated in inflammatory reactions via modulation of histamine release from mast cells. Norepinephrine 89-103 neuropeptide Y Homo sapiens 16-19 1698642-1 1990 Galanin and neuropeptide Y are known to coexist with noradrenaline in neurones of the locus coeruleus. Norepinephrine 53-66 neuropeptide Y Homo sapiens 12-26 1721688-4 1991 This action of neuropeptide Y could contribute to analgesia, particularly if this neuropeptide is co-released with noradrenaline from axon terminals in the superficial dorsal horn. Norepinephrine 115-128 neuropeptide Y Homo sapiens 15-29 2233767-5 1990 However in an adolescent boy with renal hypertension plasma concentration of noradrenaline and NPY fell following clonidine application (noradrenaline from 1.9 to 1.3 nmol/l, NPY from 3.6 to 2.4 pmol/l). Norepinephrine 77-90 neuropeptide Y Homo sapiens 175-178 2233767-5 1990 However in an adolescent boy with renal hypertension plasma concentration of noradrenaline and NPY fell following clonidine application (noradrenaline from 1.9 to 1.3 nmol/l, NPY from 3.6 to 2.4 pmol/l). Norepinephrine 137-150 neuropeptide Y Homo sapiens 95-98 2104880-2 1990 Because (a) NPY has been shown to be colocalized with noradrenaline in peripheral as well as central catecholaminergic neurons, and (b) alpha 2-adrenergic receptors of adipocytes play a major role in the regulation of lipolysis, we investigated the effect of NPY and PYY on isolated fat cells. Norepinephrine 54-67 neuropeptide Y Homo sapiens 12-15 2364490-1 1990 Neuropeptide Y (NPY) is stored with norepinephrine in sympathetic nerves throughout the cardiovascular system and is released during activation of the sympathetic nervous system in humans and other animals. Norepinephrine 36-50 neuropeptide Y Homo sapiens 0-14 2364490-1 1990 Neuropeptide Y (NPY) is stored with norepinephrine in sympathetic nerves throughout the cardiovascular system and is released during activation of the sympathetic nervous system in humans and other animals. Norepinephrine 36-50 neuropeptide Y Homo sapiens 16-19 1970339-6 1990 The results demonstrate that neuropeptide Y is colocalized with noradrenaline in most of the human sympathetic neurons and that the nerve fibres may innervate selectively the noradrenergic and cholinergic subpopulations of ganglion cells depending on the transmitters of the nerves. Norepinephrine 64-77 neuropeptide Y Homo sapiens 29-43 2174218-1 1990 The coexistence of neuropeptide Y (NPY) with noradrenaline (NA) in perivascular nerves as well as in sympathetic nerves to muscle in the heart, spleen and vas deferens suggests a role for NPY in autonomic transmission. Norepinephrine 45-58 neuropeptide Y Homo sapiens 35-38 2174219-13 1990 In addition, some of the NPY-axons in the ventral portions of striatum and cerebral cortex may be catecholaminergic, and thus originate in brainstem areas recognized to contain NPY and epinephrine or norepinephrine. Norepinephrine 200-214 neuropeptide Y Homo sapiens 25-28 2151774-6 1990 NPY is coreleased with norepinephrine by perivascular nerve endings. Norepinephrine 23-37 neuropeptide Y Homo sapiens 0-3 2346958-12 1990 Local release of neuropeptide Y during cardiac ischaemia may be involved in the regulation of coronary vascular tone as well as in the release of noradrenaline and acetylcholine. Norepinephrine 146-159 neuropeptide Y Homo sapiens 17-31 2077856-2 1990 NPY is a putative neurotransmitter mainly co-localized with noradrenaline in sympathetic fibers which innervate the cerebral vasculature. Norepinephrine 60-73 neuropeptide Y Homo sapiens 0-3 2743742-1 1989 The purpose of the present study was to evaluate whether neuropeptide Y, which coexists with noradrenaline in sympathetic nerves, may be released upon cigarette smoking. Norepinephrine 93-106 neuropeptide Y Homo sapiens 57-71 2764101-6 1989 NPY (10(-10) to 10(-6) M) exerted a direct vasoconstrictory effect on small arteries dissected from the cervix and an additive effect of NPY and norepinephrine responses was observed. Norepinephrine 145-159 neuropeptide Y Homo sapiens 0-3 2743742-4 1989 Systemic plasma levels of noradrenaline and neuropeptide Y were significantly elevated after 3 and 5 min of smoking, respectively, and reached maximal values (neuropeptide Y from 32 +/- 4 to 49 +/- 7 pmol l-1, and noradrenaline from 0.72 +/- 0.16 to 1.8 +/- 0.44 nmol l-1) 2-5 min after the smoking period. Norepinephrine 26-39 neuropeptide Y Homo sapiens 159-173 2743742-4 1989 Systemic plasma levels of noradrenaline and neuropeptide Y were significantly elevated after 3 and 5 min of smoking, respectively, and reached maximal values (neuropeptide Y from 32 +/- 4 to 49 +/- 7 pmol l-1, and noradrenaline from 0.72 +/- 0.16 to 1.8 +/- 0.44 nmol l-1) 2-5 min after the smoking period. Norepinephrine 214-227 neuropeptide Y Homo sapiens 44-58 2706916-1 1989 Neuropeptide Y (NPY) has recently been shown be co-released with noradrenaline (NA) from sympathetic nerves and to cause arterial vasoconstriction in experimental animals and man. Norepinephrine 65-78 neuropeptide Y Homo sapiens 0-14 2924733-10 1989 The effect of NPY was dose related and augmented by the addition of norepinephrine (10 nM). Norepinephrine 68-82 neuropeptide Y Homo sapiens 14-17 2481466-8 1989 These observations indicate that NPY and GAL are distributed differently in LC neurons from noradrenaline and DBH. Norepinephrine 92-105 neuropeptide Y Homo sapiens 33-36 2705532-1 1989 Neuropeptide Y (NPY) is a potent vasoconstrictor peptide contained in sympathetic nerve terminals and is co-released with norepinephrine. Norepinephrine 122-136 neuropeptide Y Homo sapiens 0-14 2705532-1 1989 Neuropeptide Y (NPY) is a potent vasoconstrictor peptide contained in sympathetic nerve terminals and is co-released with norepinephrine. Norepinephrine 122-136 neuropeptide Y Homo sapiens 16-19 2706916-1 1989 Neuropeptide Y (NPY) has recently been shown be co-released with noradrenaline (NA) from sympathetic nerves and to cause arterial vasoconstriction in experimental animals and man. Norepinephrine 65-78 neuropeptide Y Homo sapiens 16-19 2664885-5 1989 NPY seems to coexist with other on neurotransmitters like somatostatin, galanin, GABA and the catecholamines noradrenaline and adrenaline in discrete brain regions. Norepinephrine 109-122 neuropeptide Y Homo sapiens 0-3 2910096-3 1989 RESULTS: Under resting conditions, plasma NPY and norepinephrine levels were elevated in patients with CHF compared with control subjects (551 +/- 48 pg/ml versus 311 +/- 22 pg/ml, p less than or equal to 0.001 for NPY, and 306 +/- 73 pg/ml versus 124 +/- 22 pg/ml, p less than or equal to 0.02 for norepinephrine). Norepinephrine 299-313 neuropeptide Y Homo sapiens 42-45 2910096-4 1989 Plasma NPY correlated better with plasma norepinephrine than with epinephrine, indicating its origin from sympathetic nerve terminals. Norepinephrine 41-55 neuropeptide Y Homo sapiens 7-10 2743605-1 1989 Neuropeptide Y (NPY) coexists with noradrenaline in postganglionic sympathetic neurons and with noradrenaline and adrenaline in the central nervous system. Norepinephrine 35-48 neuropeptide Y Homo sapiens 0-14 2743605-1 1989 Neuropeptide Y (NPY) coexists with noradrenaline in postganglionic sympathetic neurons and with noradrenaline and adrenaline in the central nervous system. Norepinephrine 35-48 neuropeptide Y Homo sapiens 16-19 2743605-1 1989 Neuropeptide Y (NPY) coexists with noradrenaline in postganglionic sympathetic neurons and with noradrenaline and adrenaline in the central nervous system. Norepinephrine 96-109 neuropeptide Y Homo sapiens 0-14 2743605-1 1989 Neuropeptide Y (NPY) coexists with noradrenaline in postganglionic sympathetic neurons and with noradrenaline and adrenaline in the central nervous system. Norepinephrine 96-109 neuropeptide Y Homo sapiens 16-19 2699758-5 1989 Neuropeptide Y (NPY) is coreleased with noradrenaline from perivascular sympathetic nerves. Norepinephrine 40-53 neuropeptide Y Homo sapiens 0-14 2699758-5 1989 Neuropeptide Y (NPY) is coreleased with noradrenaline from perivascular sympathetic nerves. Norepinephrine 40-53 neuropeptide Y Homo sapiens 16-19 2699758-6 1989 NPY exerts prejunctional inhibitory actions on noradrenaline release and may also mediate non-adrenergic sympathetic vasoconstriction. Norepinephrine 47-60 neuropeptide Y Homo sapiens 0-3 2853756-4 1988 Exogenous neuropeptide Y reduced nerve stimulation-evoked noradrenaline overflow, possibly through a prejunctional mechanism, and caused dose-dependent vasoconstriction. Norepinephrine 58-71 neuropeptide Y Homo sapiens 10-24 3509070-1 1987 Neuropeptide Y (a recently discovered brain peptide that is colocalized with norepinephrine within some adrenergic central nervous system neurons) was measured in the cerebrospinal fluid (CSF) from patients with major affective disorder, chronic schizophrenia, and in normal volunteers. Norepinephrine 77-91 neuropeptide Y Homo sapiens 0-14 2848631-2 1988 NPY has been localized in neurons that synthesize norepinephrine or epinephrine and also in many cell bodies which are not catecholaminergic. Norepinephrine 50-64 neuropeptide Y Homo sapiens 0-3 3407677-8 1988 The vasoconstriction produced by noradrenaline was potentiated by subthreshold concentrations of NPY. Norepinephrine 33-46 neuropeptide Y Homo sapiens 97-100 2431650-2 1986 Pharmacological experiments on isolated temporal artery segments revealed that NPY potentiated the vasoconstrictor responses to noradrenaline, but had no vasoconstrictor ability or only a small vasoconstrictor ability per se. Norepinephrine 128-141 neuropeptide Y Homo sapiens 79-82 2455193-2 1987 Neuropeptide Y is stored in large dense-cored vesicles and coreleased with noradrenaline (NA) from postganglionic, sympathetic nerves, and with adrenaline (ADR) from the adrenal medulla. Norepinephrine 75-88 neuropeptide Y Homo sapiens 0-14 2455195-4 1987 Examples include the interactions of neuropeptide Y (NPY) with noradrenaline (NA) and adenosine 5"-triphosphate (ATP) released from some sympathetic nerves; vasoactive intestinal polypeptide (VIP) with acetylcholine (ACh) released from some parasympathetic nerves; and NPY and 5-hydroxytryptamine (5-HT) released from intracardiac neurones supplying coronary vessels. Norepinephrine 63-76 neuropeptide Y Homo sapiens 37-51 2455195-4 1987 Examples include the interactions of neuropeptide Y (NPY) with noradrenaline (NA) and adenosine 5"-triphosphate (ATP) released from some sympathetic nerves; vasoactive intestinal polypeptide (VIP) with acetylcholine (ACh) released from some parasympathetic nerves; and NPY and 5-hydroxytryptamine (5-HT) released from intracardiac neurones supplying coronary vessels. Norepinephrine 63-76 neuropeptide Y Homo sapiens 53-56 3755439-1 1986 Neuropeptide Y (NPY) has recently been reported to coexist with noradrenaline (NA) in central as well as peripheral noradrenergic nerves. Norepinephrine 64-77 neuropeptide Y Homo sapiens 0-14 3755439-1 1986 Neuropeptide Y (NPY) has recently been reported to coexist with noradrenaline (NA) in central as well as peripheral noradrenergic nerves. Norepinephrine 64-77 neuropeptide Y Homo sapiens 16-19 2864784-1 1985 The action of neuropeptide Y (NPY), which coexists with noradrenaline (NA) in perivascular sympathetic nerves, has been examined on feline cerebrovascular smooth muscle using a sensitive in vitro system. Norepinephrine 56-69 neuropeptide Y Homo sapiens 14-28 3755659-1 1986 Neuropeptide Y (NPY) is colocalised with noradrenaline in post-ganglionic sympathetic neurons. Norepinephrine 41-54 neuropeptide Y Homo sapiens 0-14 3755659-1 1986 Neuropeptide Y (NPY) is colocalised with noradrenaline in post-ganglionic sympathetic neurons. Norepinephrine 41-54 neuropeptide Y Homo sapiens 16-19 3755659-7 1986 The increase in NPY correlated with the increase in noradrenaline, suggesting that NPY may be released with noradrenaline when sympathetic noradrenergic nerves are activated. Norepinephrine 52-65 neuropeptide Y Homo sapiens 16-19 3755659-7 1986 The increase in NPY correlated with the increase in noradrenaline, suggesting that NPY may be released with noradrenaline when sympathetic noradrenergic nerves are activated. Norepinephrine 52-65 neuropeptide Y Homo sapiens 83-86 3755659-7 1986 The increase in NPY correlated with the increase in noradrenaline, suggesting that NPY may be released with noradrenaline when sympathetic noradrenergic nerves are activated. Norepinephrine 108-121 neuropeptide Y Homo sapiens 16-19 3755659-7 1986 The increase in NPY correlated with the increase in noradrenaline, suggesting that NPY may be released with noradrenaline when sympathetic noradrenergic nerves are activated. Norepinephrine 108-121 neuropeptide Y Homo sapiens 83-86 3914638-5 1985 It was also demonstrated, using correlative light microscopic immunostaining on serial sections and double electron microscopic immunocytochemistry, that C-PON and NPY immunoreactivities are co-localized in neuronal cell bodies of the brain cortex, sympathetic ganglion cells, norepinephrine-containing granules of the adrenal medulla and in human pheochromocytoma tumor cells. Norepinephrine 277-291 neuropeptide Y Homo sapiens 164-167 3550891-0 1986 Neuropeptide Y: coexistence with noradrenaline. Norepinephrine 33-46 neuropeptide Y Homo sapiens 0-14 3840999-2 1985 The plasma levels of neuropeptide Y correlated better with the levels of noradrenaline than adrenaline, suggesting release of a neural origin. Norepinephrine 73-86 neuropeptide Y Homo sapiens 21-35 2864784-1 1985 The action of neuropeptide Y (NPY), which coexists with noradrenaline (NA) in perivascular sympathetic nerves, has been examined on feline cerebrovascular smooth muscle using a sensitive in vitro system. Norepinephrine 56-69 neuropeptide Y Homo sapiens 30-33 29987109-2 2018 NPY (neuropeptide Y) is coreleased with norepinephrine, causes vasoconstriction via the Y1 receptor, and is degraded by DPP4 to NPY (3-36) in vitro. Norepinephrine 40-54 neuropeptide Y Homo sapiens 0-3 31468359-2 2020 In nasal mucosa, high concentrations of NPY are stored with noradrenaline in sympathetic nerve fibers. Norepinephrine 60-73 neuropeptide Y Homo sapiens 40-43 32186162-10 2019 Finally, we find that kidney invigoration method can change the concentrations of central neurotransmitters of norepinephrine and glutamate to regulate neuro-osteogenic network, and promote the recovery of ovarian function and have an estrogen-like effect by regulating the hypothalamus-pituitary-ovarian axis, which thus influences bone metabolism without clinically significant estrogen-like side effects, and regulate NPY, CGRP and SP involved in the bone metabolism. Norepinephrine 111-125 neuropeptide Y Homo sapiens 421-424 6368205-0 1984 Neuropeptide tyrosine (NPY) immunoreactivity in norepinephrine-containing cells and nerves of the mammalian adrenal gland. Norepinephrine 48-62 neuropeptide Y Homo sapiens 0-27 6368205-1 1984 The application of immunocytochemistry at both light and electron microscopic levels has revealed neuropeptide tyrosine (NPY)-immunoreactive material to be localized to norepinephrine-containing endocrine cells in the adrenal medulla and also to varicose nerve fibers penetrating the adrenal cortex of several mammalian species, including horse, cat, rat, guinea pig and mouse. Norepinephrine 169-183 neuropeptide Y Homo sapiens 98-119 6368205-1 1984 The application of immunocytochemistry at both light and electron microscopic levels has revealed neuropeptide tyrosine (NPY)-immunoreactive material to be localized to norepinephrine-containing endocrine cells in the adrenal medulla and also to varicose nerve fibers penetrating the adrenal cortex of several mammalian species, including horse, cat, rat, guinea pig and mouse. Norepinephrine 169-183 neuropeptide Y Homo sapiens 121-124 6368205-2 1984 Correlative electron microscopic immunostaining has revealed that enkephalin and NPY immunoreactivities are co-localized to the same norepinephrine-containing secretory granules. Norepinephrine 133-147 neuropeptide Y Homo sapiens 81-84 32493616-1 2020 BACKGROUND: Neuropeptide Y acts directly on the vasculature as a cotransmitter with norepinephrine for an augmented contraction. Norepinephrine 84-98 neuropeptide Y Homo sapiens 12-26 29987109-2 2018 NPY (neuropeptide Y) is coreleased with norepinephrine, causes vasoconstriction via the Y1 receptor, and is degraded by DPP4 to NPY (3-36) in vitro. Norepinephrine 40-54 neuropeptide Y Homo sapiens 5-19 29987109-3 2018 NPY (3-36) decreases release of norepinephrine via the Y2 receptor. Norepinephrine 32-46 neuropeptide Y Homo sapiens 0-3 27979380-7 2017 Interestingly, NPY decreased brain serotonin and norepinephrine concentrations in fed chicks, but increased concentrations of brain dopamine and its metabolites in fasted and fed chicks, respectively. Norepinephrine 49-63 neuropeptide Y Homo sapiens 15-18 28423914-4 2017 Neuropeptide Y is co-localized with noradrenaline in central and sympathetic nervous systems. Norepinephrine 36-49 neuropeptide Y Homo sapiens 0-14 27979380-8 2017 Plasma epinephrine was decreased by NPY in fed chicks, but plasma concentrations of norepinephrine and epinephrine were increased significantly by NPY in fasted-heat exposed chicks. Norepinephrine 84-98 neuropeptide Y Homo sapiens 147-150 15003356-4 2004 Oxidized NPY, like native NPY, potentiated the noradrenaline and adenosine 5"-triphospahate-induced vasoconstriction, an effect blocked by BIBP 3226 and consonant with the RT-PCR detection of the mRNA encoding the NPY Y1 receptor. Norepinephrine 47-60 neuropeptide Y Homo sapiens 9-12 26008896-2 2015 Neuropeptide Y (NPY) is a neurotransmitter that is co-released with norepinephrine and is up-regulated during increased sympathetic activity. Norepinephrine 68-82 neuropeptide Y Homo sapiens 0-14 26008896-2 2015 Neuropeptide Y (NPY) is a neurotransmitter that is co-released with norepinephrine and is up-regulated during increased sympathetic activity. Norepinephrine 68-82 neuropeptide Y Homo sapiens 16-19 25344273-6 2015 In these conditions, sympathetic neurotransmitters such as neuropeptide Y (NPY) can be released in addition to noradrenaline, and plasma levels correlate with infarct size and mortality. Norepinephrine 111-124 neuropeptide Y Homo sapiens 59-73 16612252-9 2006 By contrast, NPY acted less specifically, blocking norepinephrine release triggered by either nicotine or membrane depolarization. Norepinephrine 51-65 neuropeptide Y Homo sapiens 13-16 15850450-1 2005 BACKGROUND INFORMATION: NPY (neuropeptide Y) may have an effect on the properties of vascular endothelial cells such as pro-angiogenic effects and potentiation of noradrenaline-induced vasoconstriction. Norepinephrine 163-176 neuropeptide Y Homo sapiens 24-27 15850450-1 2005 BACKGROUND INFORMATION: NPY (neuropeptide Y) may have an effect on the properties of vascular endothelial cells such as pro-angiogenic effects and potentiation of noradrenaline-induced vasoconstriction. Norepinephrine 163-176 neuropeptide Y Homo sapiens 29-43 15464018-4 2004 In addition, the detection of the diverse receptor populations for ATP, noradrenaline and NPY in blood vessels, either in the smooth muscle, endothelial cells or nerve endings, further contribute to the notion that sympathetic vascular reflexes encompass the orchestrated action of the noradrenaline and ATP, and their modulation by NPY. Norepinephrine 286-299 neuropeptide Y Homo sapiens 90-93 15464018-4 2004 In addition, the detection of the diverse receptor populations for ATP, noradrenaline and NPY in blood vessels, either in the smooth muscle, endothelial cells or nerve endings, further contribute to the notion that sympathetic vascular reflexes encompass the orchestrated action of the noradrenaline and ATP, and their modulation by NPY. Norepinephrine 286-299 neuropeptide Y Homo sapiens 333-336 28508370-5 2017 Tyrosine hydroxylase, dopamine beta hydroxylase are the key enzymes for the synthesis of norepinephrine; and neuropeptide Y (NPY) is the peptide that is co-stored and co-released with norepinephrine. Norepinephrine 89-103 neuropeptide Y Homo sapiens 109-123 28508370-5 2017 Tyrosine hydroxylase, dopamine beta hydroxylase are the key enzymes for the synthesis of norepinephrine; and neuropeptide Y (NPY) is the peptide that is co-stored and co-released with norepinephrine. Norepinephrine 89-103 neuropeptide Y Homo sapiens 125-128 28508370-5 2017 Tyrosine hydroxylase, dopamine beta hydroxylase are the key enzymes for the synthesis of norepinephrine; and neuropeptide Y (NPY) is the peptide that is co-stored and co-released with norepinephrine. Norepinephrine 184-198 neuropeptide Y Homo sapiens 109-123 28508370-5 2017 Tyrosine hydroxylase, dopamine beta hydroxylase are the key enzymes for the synthesis of norepinephrine; and neuropeptide Y (NPY) is the peptide that is co-stored and co-released with norepinephrine. Norepinephrine 184-198 neuropeptide Y Homo sapiens 125-128 24757681-1 2014 Neuropeptide Y was isolated from the porcine brain in 1982 and shown to be colocalized with noradrenaline in sympathetic nerve terminals. Norepinephrine 92-105 neuropeptide Y Homo sapiens 0-14 21729140-1 2012 Neuropeptide Y (NPY) has been shown to induce contraction of isolated human penile erectile tissue and potentiate the response to noradrenaline. Norepinephrine 130-143 neuropeptide Y Homo sapiens 0-20 15003356-4 2004 Oxidized NPY, like native NPY, potentiated the noradrenaline and adenosine 5"-triphospahate-induced vasoconstriction, an effect blocked by BIBP 3226 and consonant with the RT-PCR detection of the mRNA encoding the NPY Y1 receptor. Norepinephrine 47-60 neuropeptide Y Homo sapiens 26-29 15003356-4 2004 Oxidized NPY, like native NPY, potentiated the noradrenaline and adenosine 5"-triphospahate-induced vasoconstriction, an effect blocked by BIBP 3226 and consonant with the RT-PCR detection of the mRNA encoding the NPY Y1 receptor. Norepinephrine 47-60 neuropeptide Y Homo sapiens 26-29 14514739-4 2003 Univariate analysis revealed that plasma NPY was directly related to plasma norepinephrine (r = 0.37, P < 0.001) and epinephrine (r = 0.17, P = 0.005), exceeding the upper limit of the normal range in the majority of patients with end-stage renal disease (170 of 277, 61%). Norepinephrine 76-90 neuropeptide Y Homo sapiens 41-44 14514739-7 2003 Plasma NPY maintained its predictive power for CV events in statistical model including plasma norepinephrine. Norepinephrine 95-109 neuropeptide Y Homo sapiens 7-10 12488332-0 2003 Immunolesion of norepinephrine and epinephrine afferents to medial hypothalamus alters basal and 2-deoxy-D-glucose-induced neuropeptide Y and agouti gene-related protein messenger ribonucleic acid expression in the arcuate nucleus. Norepinephrine 16-30 neuropeptide Y Homo sapiens 123-137 12444905-1 2002 Neuropeptide Y (NPY) is co-released with noradrenaline from sympathetic nerves, has a strong vasoconstrictive action, and causes an attenuation of parasympathetic action in animal experiments. Norepinephrine 41-54 neuropeptide Y Homo sapiens 0-14 12444905-1 2002 Neuropeptide Y (NPY) is co-released with noradrenaline from sympathetic nerves, has a strong vasoconstrictive action, and causes an attenuation of parasympathetic action in animal experiments. Norepinephrine 41-54 neuropeptide Y Homo sapiens 16-19 10700334-1 1999 Neuropeptide Y(NPY) co-exists with norepinephrine in the sympathetic nervous system, and NPY may represent the sympathetic-neuronal output. Norepinephrine 35-49 neuropeptide Y Homo sapiens 0-19 11080198-0 2000 Neuropeptide Y cotransmission with norepinephrine in the sympathetic nerve-macrophage interplay. Norepinephrine 35-49 neuropeptide Y Homo sapiens 0-14 11080198-2 2000 To study the nerve-macrophage communication, a superfusion method was used to investigate cotransmission of neuropeptide Y (NPY) with norepinephrine (NE), with interleukin (IL)-6 secretion used as the macrophage read-out parameter. Norepinephrine 134-148 neuropeptide Y Homo sapiens 124-127 10961962-2 2000 Neuropeptide Y (NPY), which is costored and released with norepinephrine (NE) during sympathetic activity, is a potent vasoconstrictor with a relatively long half-life. Norepinephrine 58-72 neuropeptide Y Homo sapiens 0-14 10961962-2 2000 Neuropeptide Y (NPY), which is costored and released with norepinephrine (NE) during sympathetic activity, is a potent vasoconstrictor with a relatively long half-life. Norepinephrine 58-72 neuropeptide Y Homo sapiens 16-19 10715359-2 2000 In turn, neuropeptide Y (NPY) has been shown to inhibit the release of norepinephrine from sympathetic noradrenergic neurons. Norepinephrine 71-85 neuropeptide Y Homo sapiens 9-23 10715359-2 2000 In turn, neuropeptide Y (NPY) has been shown to inhibit the release of norepinephrine from sympathetic noradrenergic neurons. Norepinephrine 71-85 neuropeptide Y Homo sapiens 25-28 10629875-5 1999 And norepinephrine enhanced the effect of neuropeptide Y on lung vascular permeability. Norepinephrine 4-18 neuropeptide Y Homo sapiens 42-56 10475560-2 1999 The study focused on the autonomic messengers neuropeptide Y (NPY), tyrosine hydroxylase (TH), the rate-limiting enzyme in the synthesis of noradrenaline (NA), and vasoactive intestinal polypeptide (VIP). Norepinephrine 140-153 neuropeptide Y Homo sapiens 46-60 10475560-2 1999 The study focused on the autonomic messengers neuropeptide Y (NPY), tyrosine hydroxylase (TH), the rate-limiting enzyme in the synthesis of noradrenaline (NA), and vasoactive intestinal polypeptide (VIP). Norepinephrine 140-153 neuropeptide Y Homo sapiens 62-65 12106798-3 2002 The possible actions of neuropeptide Y, that is co-localized and released with noradrenaline, as a sympathetic co-transmitter has attracted much attention during the last decade. Norepinephrine 79-92 neuropeptide Y Homo sapiens 24-38 11867178-5 2002 NPY levels correlated inversely with renal plasma flow and glomerular filtration rate and directly with norepinephrine. Norepinephrine 104-118 neuropeptide Y Homo sapiens 0-3 10205006-0 1999 Adenosine 5"-triphosphate and neuropeptide Y are co-transmitters in conjunction with noradrenaline in the human saphenous vein. Norepinephrine 85-98 neuropeptide Y Homo sapiens 30-44 9608581-4 1998 NPY is a 36 amino acid peptide neurotransmitter located in sympathetic and nonsympathetic nerve fibers, as well as in brain structures such as the locus coeruleus, where it is colocalized with norepinephrine. Norepinephrine 193-207 neuropeptide Y Homo sapiens 0-3 10073744-1 1999 AIMS: Neuropeptide Y (NPY) is a sympathetic neurotransmitter released with noradrenaline during sympathetic stimulation. Norepinephrine 75-88 neuropeptide Y Homo sapiens 6-20 10073744-1 1999 AIMS: Neuropeptide Y (NPY) is a sympathetic neurotransmitter released with noradrenaline during sympathetic stimulation. Norepinephrine 75-88 neuropeptide Y Homo sapiens 22-25 9608581-5 1998 NPY has been shown to inhibit locus coeruleus neuronal firing, decrease norepinephrine release, and increase postsynaptic noradrenergic signal transduction. Norepinephrine 72-86 neuropeptide Y Homo sapiens 0-3 9630349-2 1998 We investigated the potentiating effect of low concentrations of neuropeptide Y (NPY) on the vasoconstriction induced by transmural nerve stimulation (TNS) and noradrenaline (NA) in human saphenous veins. Norepinephrine 160-173 neuropeptide Y Homo sapiens 65-79 9590190-10 1998 In stepwise multiple regression analysis, NPY alone explained blood pressure elevation when analyzed with fluid overload and angiotensin II, renin, noradrenaline, and adrenaline levels. Norepinephrine 148-161 neuropeptide Y Homo sapiens 42-45 9669490-2 1998 One such mediator is neuropeptide Y (NPY), which is co-localized with noradrenaline in sympathetic perivascular nerves. Norepinephrine 70-83 neuropeptide Y Homo sapiens 21-35 9669490-2 1998 One such mediator is neuropeptide Y (NPY), which is co-localized with noradrenaline in sympathetic perivascular nerves. Norepinephrine 70-83 neuropeptide Y Homo sapiens 37-40 9630349-2 1998 We investigated the potentiating effect of low concentrations of neuropeptide Y (NPY) on the vasoconstriction induced by transmural nerve stimulation (TNS) and noradrenaline (NA) in human saphenous veins. Norepinephrine 160-173 neuropeptide Y Homo sapiens 81-84